Related Experiment Videos
[Effect of bezafibrate in isolated hypercholesterolemia and mixed hyperlipidemia on infarct risk (Stepwise Program
H Sinzinger1, I Virgolini, P Kudlacek
1Atheroskleroseforschungsgruppe (ASF) Wien.
Insights
Bezafibrate effectively treats high cholesterol and triglycerides, significantly lowering coronary heart disease risk in patients with hyperlipidemia. This study demonstrates bezafibrate
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Disorders
Background:
- Hypercholesterolemia and mixed hyperlipidemia are significant risk factors for coronary heart disease.
- Effective lipid-lowering therapies are crucial for managing cardiovascular risk.
Purpose of the Study:
- To evaluate the therapeutic effects of bezafibrate on plasma lipids and coronary risk.
- To assess bezafibrate's efficacy in patients with isolated hypercholesterolemia and mixed hyperlipidemia.
Main Methods:
- An open, prospective, multicenter study involving 763 patients.
- 16-week treatment with bezafibrate (400 mg/day).
- Lipid profiles (total cholesterol, triglycerides, LDL-C, HDL-C) and coronary risk (SPIRIT calculator) were assessed.
Main Results:
- Bezafibrate significantly reduced total cholesterol (-22%), LDL-C (-20%), and triglycerides (-32%).
- HDL-C levels increased by 29.6%, and the C/HDL-C ratio decreased by 36%.
- Coronary risk factor score decreased by 54.5%, with a 50.4% reduction in calculated myocardial infarction incidence.
Conclusions:
- Bezafibrate demonstrates potent hypolipidemic effects in both isolated hypercholesterolemia and mixed hyperlipidemia.
- The drug effectively improves lipid metabolism and significantly reduces calculated coronary risk.
- Bezafibrate is a valuable therapeutic option for managing dyslipidemia and associated cardiovascular risks.
Abstract:
The therapeutic effect of bezafibrate (1 x 400 mg/day) on plasma lipids and coronary risk was evaluated in an open, prospective multicenter study in 763 patients with isolated hypercholesterolemia or mixed hyperlipidemia. During the 16 weeks of treatment (712 patients were included in the evaluation) bezafibrate lowered total cholesterol (C) by 22%, triglycerides (TG) by 32% and LDL-C by 20% and increased HDL-C by 29.6%. The ratio of C/HDL-C decreased from 8.8 +/- 2.0 to 5.4 +/- 1.5, i.e. a reduction of 36%. A comparable hypolipemic effect of bezafibrate was seen in all the subgroups of isolated hypercholesterolemia (C -21%, LDL-C -31%, HDL-C + 28%, TG -10%) and mixed hyperlipidemia (C -22%, LDL-C -16%, HDL-C + 30%, TG -37%). During treatment the coronary risk factor estimated by the SPIRIT calculator decreased from 5.5 to 2.5 (-54.5%) in male patients (n = 499). The calculated incidence of myocardial infarction thereby decreased from 225.7 to 111.9 (-50.4%). This study shows that bezafibrate effectively improves lipid metabolism in both isolated hypercholesterolemia and mixed hyperlipidemia and results in a decreased coronary risk.